ViiV says early-stage data on VH184 for HIV could support twice-yearly dosing
Source: SeekingAlpha
2026-02-25 15:50:28 ET
More on GSK, Pfizer
- Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- 15 states sue Trump administration over changes to U.S. vaccine schedule
- GSK to acquire Canada's 35Pharma for $950M in cash
Read the full article on Seeking Alpha
For further details see:
ViiV says early-stage data on VH184 for HIV could support twice-yearly dosing
Shionogi & Co Ltd
NASDAQ: SGIOF
SGIOF Trading
0.0% G/L:
$23.105 Last:
800 Volume:
$25.373 Open:
